CBIO vs NVCT: stock comparison and AI forecast
Gyre Therapeutics, Inc. (CBIO) and Nuvectis Pharma, Inc. (NVCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CBIO Gyre Therapeutics, Inc.
- Price
- $12.94 -28.1% · 6M
- Market Cap
- $554M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVCT Nuvectis Pharma, Inc.
- Price
- $17.76 +72.1% · 6M
- Market Cap
- $579M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- CBIO and NVCT have similar market capitalizations ($554M and $579M).
- Over the last six months NVCT returned +72.1% and CBIO -28.1%.
- CBIO carries 0.32 times debt per unit of equity, against 0.11 times for NVCT.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CBIO | NVCT |
|---|---|---|
| Market Cap | $554M | $579M |
| P/B Ratio | 5.13x | 4.57x |
| EPS | $-0.10 | $-1.90 |
| Book Value/Share | $2.52 | $3.89 |
| Revenue/Share | $2.81 | – |
| FCF/Share | $-0.37 | – |
Profitability & Margins
| Metric | CBIO | NVCT |
|---|---|---|
| ROE | – | -39.8% |
| ROA | – | -35.8% |
| ROIC | -9.8% | -41.2% |
| Gross Margin | 94.3% | – |
| Operating Margin | -13.9% | – |
| EBT Margin | -13.4% | – |
| Tax Rate | -21.4% | – |
Financial Health
| Metric | CBIO | NVCT |
|---|---|---|
| Current Ratio | 4.26x | 9.92x |
| Quick Ratio | 3.86x | – |
| D/E Ratio | 0.32x | 0.11x |
| Financial Leverage | 1.85x | 1.11x |
| Interest Coverage | -19.4x | – |
| Working Capital | $93M | $127M |
Cash Flow
| Metric | CBIO | NVCT |
|---|---|---|
| Operating Cash Flow | -$14M | -$40M |
| Free Cash Flow | -$16M | – |
| Capital Spending | -$1M | – |
| OCF Growth YoY | -1663.9% | – |
| FCF/Sales | -13.1% | – |
| CapEx/Sales | 1.0% | – |
Operational Efficiency
| Metric | CBIO | NVCT |
|---|---|---|
| Asset Turnover | 0.60x | – |
| Receivables Turnover | 4.3x | – |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 4.4x | – |
| Days Sales Outstanding | 84 days | – |
| Days Inventory | 613 days | – |
| Payables Period | 66 days | – |
| Cash Conversion Cycle | 631 days | – |
Income Statement
| Metric | CBIO | NVCT |
|---|---|---|
| Total Revenue | $120M | – |
| Operating Income | -$17M | -$52M |
| Net Income | – | -$50M |
| R&D Expense | $17M | $41M |
| SG&A Expense | $96M | – |
| Cost of Goods Sold | $7M | – |
Dividend & Shareholder Information
| Metric | CBIO | NVCT |
|---|---|---|
| Shares Outstanding | 43M | 33M |
| EPS Growth | -350.0% | – |
CBIO vs NVCT: stock comparison and AI forecast
Which is bigger, CBIO or NVCT?
CBIO and NVCT have similar market capitalizations ($554M and $579M).
Which stock performed better over the last six months, CBIO or NVCT?
Over the last six months NVCT returned +72.1% and CBIO -28.1%.
Which one does Intratio's AI model rank higher, CBIO or NVCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.